|
1
|
Hamperl H: The myothelia (myoepithelial
cells). Normal state; regressive changes; hyperplasia; tumors. Curr
Top Pathol. 53:161–220. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheung KL, Wong AWS, Parker H, Li VWY,
Winterbottom L, Morgan DAL and Ellis IO: Pathological features of
primary breast cancer in the elderly based on needle core
biopsies-a large series from a single centre. Crit Rev Oncol
Hematol. 67:263–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foschini MP, Geyer FC, Hayes MM, Marchio C
and Nishimura R: Adenomyoepithelioma. In: WHO classification of
tumours. Breast tumours. 5th edition. IARC; Lyon: pp. 43–45.
2018
|
|
4
|
Ali RH and Hayes MM: Combined
epithelial-myoepithelial lesions of the breast. Surg Pathol Clin.
5:661–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Foschini MP, Geyer FC, Hayes MM, Marchio C
and Nishimura R: Malignant adenomyoepithelioma. In: WHO
classification of tumours. Breast tumours. 5th edition. IARC; Lyon:
pp. 46–48. 2018
|
|
6
|
The Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Geyer FC, Li A, Papanastasiou AD, Smith A,
Selenica P, Burke KA, Edelweiss M, Wen HC, Pisculoglio S,
Schultheis AM, et al: Recurrent hotspot mutations in HRAS Q61 and
PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.
Nature Commun. 9:18162018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prior IA, Hood FE and Hartley JL: The
frequency of Ras mutations in cancer. Cancer Res. 80:2969–2974.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Urano M, Nakaguro M, Yamamoto Y, Hirai H,
Tanigawa M, Saigusa N, Shimizu A, Tsukahara K, Tada Y, Sakurai K,
et al: Diagnostic significance of HRAS mutations in
epithelial-myoepithelial carcinomas exhibiting a broad
histopathologic spectrum. Am J Surg Pathol. 43:984–994. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nigam A, Krishnamoorthy GP, Chatila WK,
Berman K, Saqcena M, Walch H, Venkatramani M, Ho AL, Schltz N,
Fagin JA and Untch BR: Cooperative genomic lesions in HRAS-mutant
cancers predict resistance to farnesyltransferase inhibitors.
Oncogene. 43:2806–2819. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimura T, Tada Y, Hirai H, Kawakita D,
Kano S, Tsukahara K, Shimizu A, Takase S, Imanishi Y, Ozawa H, et
al: Prognostic and histogenetic roles of gene alteration and the
expression of key potentially actionable targets in salivary duct
carcinomas. Oncotarget. 9:1852–1867. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lubin D, Toorens E, Zhang PJ, Jaffer S,
Baraban E, Bleiweiss IJ and Nayak A: Adenomyoepitheliomas of the
breast frequently harbor recurrent hotspot mutations in PIK3-AKT
pathway-related genes and a subset show genetic similarity to
salivary gland epithelial-myoepithelial carcinoma. Am J Surg
Pathol. 43:1005–1013. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ginter PS, Mcintire PJ, Kurtis B,
Mirabelli S, Motanagh S, Hoda S, Elemento O, Shin SJ and Mosquera
JM: Adenomyoepithelial tumors of the breast: Molecular
underpinnings of a rare entity. Mod Pathol. 33:1764–1772. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bièche I, Coussy F, El-Botty R, Vacher S,
Château-Joubert S, Dahmani A, Montaudon E, Reyes C, Gentien D,
Reyal F, et al: HRAS is a therapeutic target in malignant
chemo-resistant adenomyoepithelioma of the breast. J Hematol Oncol.
14:1432021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmed AA and Heller DS: Malignant
adenomyoepithelioma of the breast with malignant proliferation of
epithelial and myoepithelial elements. A case report and review of
the literature. Arch Pathol Lab Med. 124:632–636. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seifert G: Are adenomyoepithelioma of the
breast and epithelial-myoepithelial carcinoma of the salivary
glands identical tumours? Virchow Arch. 433:285–287. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parsons L, Chen A, Bertus B, Beatty C,
Stashower J, Tomboc P, Brooke S and Zinn Z: Topical trametinib for
agminated spitz nevi harboring HRAS mutation. Pediatric Dermatol.
42:841–843. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alqudaihi HMA, Lee SB, Son BH, Ahn SH, Lee
JW, Ko BS, Kim HJ, Chung IY, Kim J and Gog G: Clinicopathological
characteristics and outcomes of malignant adenomyoepithelioma of
the breast: A single institution's experience. World J Surg Oncol.
20:1282022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bult P, Verwiel JM, Wobbes T, Kooy-Smits
MM, Biert J and Holland R: Malignant adenomyoepithelioma of the
breast with metastasis in the thyroid gland 12 years after excision
of the primary tumor. Case report and review of the literature.
Virchow Arch. 436:158–166. 2000. View Article : Google Scholar : PubMed/NCBI
|
